TipRanks
Go Ultimate55% OFF

HeraMED Ltd. (1I4) AI Stock Analysis

DE:1I4

HeraMED Ltd.

(Frankfurt:1I4)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Gross Margin ImprovementThe improvement to roughly 60% gross margin shows that the company’s offerings can generate positive contribution after direct costs. If maintained, this creates a stronger foundation for scaling revenue, funding product development, and eventually converting improved unit economics into operating profitability.
Negative Factors
Revenue ContractionRecent revenue contraction weakens the company’s ability to spread fixed operating costs across a growing base and makes a path to profitability less certain. Continued volatility or decline could constrain investment capacity, reduce operating leverage, and limit the commercial impact of its digital health platform.

HeraMED Ltd. (1I4) vs. iShares MSCI Germany ETF (EWG)

-25%0%25%50%75%100%125%DE:1I4+33.33%EWG+6.61%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 26.80M
Dividend Yield
―
Average Volume (3M)
40.29K
Price to Earnings (P/E)
-11.4
Beta (1Y)
0.99
Revenue Growth
-55.21%
EPS Growth
41.94%
Country
Germany
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

HeraMED Ltd. Business Overview & Revenue Model

Company Description

HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe,...

HeraMED Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:1I4 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:RMDAU:RMD84OutperformAUD 46.25B21.2025.14%0.97%1.54%4.43%
AU:CMPAU:CMP54NeutralAUD 47.94M209.090.93%―18.54%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:AT1AU:AT145NeutralAUD 12.63M-3.33-48.97%―40.65%45.45%
AU:UCMAU:UCM43NeutralAUD 3.12M-1.56-1788.57%―-52.22%44.79%
AU:IPDAU:IPD39UnderperformAUD 14.66M-0.34-259.31%―14.85%-1.74%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:1I4AU:CMPAU:IPDAU:UCMAU:AT1AU:RMDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:1I4 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:1I4HeraMED Ltd.0.020.0011.11%
AU:CMPCompumedics Limited0.22-0.10-31.25%
AU:IPDImpedimed Limited0.01-0.02-63.16%
AU:UCMUscom Limited0.010.000.00%
AU:AT1Atomo Diagnostics Ltd.0.01-0.02-53.33%
AU:RMDResmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh33.46-3.91-10.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.